Q4 Earnings Forecast for Arvinas Issued By Leerink Partnrs

Arvinas, Inc. (NASDAQ:ARVN) – Investment analysts at Leerink Partnrs issued their Q4 2025 EPS estimates for Arvinas in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.93) per share for the quarter. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share. Leerink Partnrs also issued estimates for Arvinas’ FY2027 earnings at $1.05 EPS.

A number of other research firms have also recently commented on ARVN. Stephens began coverage on Arvinas in a research note on Monday, November 18th. They issued an “overweight” rating and a $55.00 target price on the stock. Barclays reduced their price objective on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research note on Monday. Oppenheimer dropped their target price on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. Guggenheim reissued a “buy” rating on shares of Arvinas in a research report on Thursday, December 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a research report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $61.45.

Arvinas Trading Down 2.5 %

Shares of Arvinas stock opened at $19.10 on Friday. Arvinas has a 1 year low of $16.61 and a 1 year high of $53.08. The company has a 50-day moving average of $19.75 and a 200 day moving average of $23.67.

Institutional Trading of Arvinas

Several institutional investors have recently made changes to their positions in the business. FMR LLC grew its holdings in Arvinas by 7.6% during the 3rd quarter. FMR LLC now owns 2,883,604 shares of the company’s stock valued at $71,023,000 after buying an additional 204,317 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Arvinas by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock valued at $57,371,000 after acquiring an additional 367,343 shares in the last quarter. Braidwell LP increased its holdings in Arvinas by 148.3% in the 3rd quarter. Braidwell LP now owns 1,284,472 shares of the company’s stock valued at $31,637,000 after acquiring an additional 767,242 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its stake in Arvinas by 1.4% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,244,450 shares of the company’s stock worth $30,651,000 after purchasing an additional 17,723 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Arvinas by 1.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 536,112 shares of the company’s stock valued at $10,277,000 after purchasing an additional 5,443 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.